Marker Therapeutics announced it has been awarded a $16.2 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This significant non-dilutive funding will be used to advance the company's lead investigational MAR-T cell therapy, MT-601 (neldaleucel), in a planned Phase 2 clinical trial.

Key Details

  • Grant Award: Received a $16.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
  • Purpose of Funds: To support the advancement of lead therapy MT-601 (neldaleucel) in the planned Phase 2 APOLLO study.
  • Clinical Focus: The study will evaluate MT-601 in patients with relapsed or refractory large B-cell lymphoma following treatment with CD19-directed CAR-T cells.